Will a French company revolutionize the pharmaceutical industry? It may well be that with your help, and thanks to blockchain technology, such a feat is about to be realized. Today, HCS Pharma is launching a fundraiser through a Security Token Offering (STO). Let’s discover together this promising startup, specialized in the creation of in-vitro organs.
Le Journal du Coin offers you this promotional article in collaboration with HCS Pharma.
A company rooted in pharmaceutical research
HCS Pharma was founded in 2014 by Nathalie Maubon, Doctor in Pharmaceutical Research and Development. A distinguished scientist with over 20 years of experience in her area of expertise.
At the origin of this adventure, the observation that the search for new medical treatments encounters many pitfalls. First of all the time factor. Indeed, it takes an average of 12 years to study and develop a new molecule. Cost is also a critical factor. Budgets are on average $2 billion for a drug. A colossal investment and until now incompressible at the expense of the laboratories. A waste of time and money without any guarantee of success since in the end, with 90% of failures, this traditional process remains very ineffective.
Indeed, current methods for testing potential drugs apply to cells taken out of their environment and cultured on plastic. Under these conditions, they drift very quickly and end up no longer resembling what they would be in their original environment. This therefore does not make it possible to obtain relevant results as to what future drugs could give in humans. For comparison, you can very well germinate lentils on damp cotton. However, you will never get the actual growing conditions this way. It lacks all the nutrients and microbiota present in the ground.
The Biomimesys solution
The challenge, therefore, was to find an environment that approximates as closely as possible to that of the body to grow the human cells and test the molecules more efficiently. It is to meet this need that HCS Pharma has designed Biomimesys. This solution faithfully reproduces the environment of cells in an organ, also called the extra-cellular matrix. This is specific to each biological tissue and organ.
The technique, already proven, allows greater research efficiency with a success rate of more than 90% and the search for drugs much more effective against so-called complex diseases, such as cancer, Parkinson’s or Alzheimer’s. A real feat compared to the high failure rate of conventional methods, ultimately leading to ineffective drugs. The production costs of the laboratories are consequently divided by 7 or 8, reinforcing the efficiency of the colossal investments that it requires. The duration of the tests necessary for the development of a drug is halved.
The company is already participating in several research and development programs in various fields such as neurology or oncology. It also naturally finds its place in cosmetology to overcome the ban on animal testing. It offers artificial skin for this. The ultimate goal is to reproduce whole and functional organs for the sole purpose of regenerative medicine.
Join the adventure “in-crypto”
In order to pursue its development, HCS Pharma now wishes to raise 7 million euros. As an innovative company, it turned to a financing solution that the crypto industry has been able to highlight. It therefore launched an STO on the Swiss platform EDSX. The company had previously obtained financing of more than 2 million euros thanks to a similar operation on Capital Cell. A Catalan platform dedicated to biotechnologies and health.
As a reminder, the tokens acquired during this sale are “Security token”. This means that they correspond to real shares of the company’s capital. They therefore confer rights identical to those of holders of conventional securities. HCS Pharma is planning an IPO on the Frankfurt Stock Exchange in the third quarter of 2022. From then on, these tokens will be exchangeable for shares. They may be kept or resold immediately since from the listing, no blocking period is provided.
The company wanted the acquisition of shares to remain accessible to as many people as possible. Therefore, the minimum investment is €500, which is quite remarkable for a company of this type. Additionally, EDSX accepts settlements in cryptocurrencies. The price of the token is set at 1 euro, i.e. a 20% discount on the final price expected in the event of an IPO.
With this STO, HCS Pharma demonstrates that crypto financing modes can help support a large number of companies rooted in the real economy. On this occasion, you are given the opportunity to take part in a major innovation in the field of research. The proven effectiveness of the Biomimesys solution makes it possible to obtain concrete results in the short term and at a lower cost. A market worth several hundred billion dollars and growing every year. A scientific revolution which reaches out to the crypto ecosystem. Will you be part of the next medical revolution?
It is important to understand that investing in an STO, no matter how serious, involves risk. No one can guarantee the success of a project. Only invest money you can afford to lose.